2,851
edits
Quercetin: Difference between revisions
→Pharmacological Properties
| Line 39: | Line 39: | ||
| Co-administration with Piperine || Approximately 20% || Inhibits metabolism of quercetin, improving its bioavailability. | | Co-administration with Piperine || Approximately 20% || Inhibits metabolism of quercetin, improving its bioavailability. | ||
|} | |} | ||
=== Metabolism and Bioavailability === | === Metabolism and Bioavailability === | ||
Once absorbed, quercetin undergoes extensive first-pass metabolism in the liver and intestines, where it is converted into various metabolites through glucuronidation, sulfation, and methylation. The extensive metabolism significantly reduces the concentrations of free quercetin in the plasma, limiting its bioavailability. The metabolites, however, may retain some biological activity and contribute to the overall effects of quercetin in the body. | Once absorbed, quercetin undergoes extensive first-pass metabolism in the liver and intestines, where it is converted into various metabolites through glucuronidation, sulfation, and methylation. The extensive metabolism significantly reduces the concentrations of free quercetin in the plasma, limiting its bioavailability. The metabolites, however, may retain some biological activity and contribute to the overall effects of quercetin in the body. | ||
=== Implications of Low Bioavailability === | |||
The low bioavailability of quercetin raises questions about the clinical relevance of its potential health benefits observed in vitro and in animal studies. It necessitates the need for effective delivery systems and formulations to realize its therapeutic potential in humans. Additionally, understanding the biological activities of its metabolites is crucial, as they are the predominant forms present in systemic circulation. | |||
=== Mode of Action === | === Mode of Action === | ||